Whitehawk Therapeutics, Inc. Common Stock WHWK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Product | ||||||
| Antibody Drug Conjugate | $71.13M+1,085% | $59.09M+885% | $54.7M— | $49.45M— | $6M— | |
| FYARRO | -$137K-100% | $5.17M-84.9% | $10.35M— | $19.47M— | $29.38M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Whitehawk Therapeutics, Inc. Common Stock break its business down?
- Whitehawk Therapeutics, Inc. Common Stock (WHWK) reports research and development expense excluding acquired in process cost by product across 2 parts — Antibody Drug Conjugate and FYARRO. Each is extracted from the segment footnotes and tracked over time.
- Where does Whitehawk Therapeutics, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Whitehawk Therapeutics, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.